Goldman Sachs Downgrades Enfusion to Sell, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Gabriela Borges downgraded Enfusion (NYSE:ENFN) from Neutral to Sell and reduced the price target from $9 to $8.
February 28, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs downgraded Enfusion from Neutral to Sell and lowered the price target from $9 to $8.
A downgrade by a major financial institution like Goldman Sachs can significantly impact investor sentiment and stock price. The reduction in price target further emphasizes a bearish outlook, likely leading to a short-term decrease in ENFN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100